Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation

[cafead]

via

• Lead Program, THB001, a First-In-Class, Highly Selective, Oral KIT Inhibitor in Development for Multiple Allergic and Inflammatory Conditions, Is Currently in Phase 1 Clinical Development
• $155 Million Raised to Date Expected to Fund Operations Beyond Completion of a Proof-of-Concept Study in Chronic Urticaria

article source